RaySearch Laboratories AB (STU:27R) ROCE %: 18.86% (As of Mar. 2026)


STU:27R RaySearch Laboratories AB STU:27R
83 GF Score
Price €19.38
GF Value €17.14
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is RaySearch Laboratories AB ROCE %?

RaySearch Laboratories AB STU:27R +2.65% 83 ROCE % is 18.86% as of Mar. 2026. GuruFocus rates STU:27R with a GF Score™ of 83/100 and a GF Value™ of €17.14 (Modestly Overvalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. RaySearch Laboratories AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 18.86%.

RaySearch Laboratories AB  (STU:27R) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

RaySearch Laboratories AB ROCE % Related Terms

RaySearch Laboratories AB ROCE % Historical Data

* Premium members only.

The historical data trend for RaySearch Laboratories AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaySearch Laboratories AB ROCE % Chart

RaySearch Laboratories AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.03 3.44 9.44 20.13 21.62

RaySearch Laboratories AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.87 10.60 26.48 26.43 18.86
STU:27R
83GF Score
RaySearch Laboratories AB STU:27R
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaySearch Laboratories AB ROCE % Calculation

RaySearch Laboratories AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=27.163/( ( (181.802 - 61.186) + (183.049 - 52.369) )/ 2 )
=27.163/( (120.616+130.68)/ 2 )
=27.163/125.648
=21.62 %

RaySearch Laboratories AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=25.14/( ( (183.049 - 52.369) + (188.24 - 52.287) )/ 2 )
=25.14/( ( 130.68 + 135.953 )/ 2 )
=25.14/133.3165
=18.86 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 18.86% mean?
RaySearch Laboratories AB (STU:27R) has a ROCE % of 18.86% as of Mar. 2026.
Is RaySearch Laboratories AB's ROCE % too high?
RaySearch Laboratories AB's current ROCE % is 18.86%. The Healthcare Providers & Services industry median ROCE % is 6.43. RaySearch Laboratories AB's value of 18.86% is 193.3% above this industry median. Overall, RaySearch Laboratories AB has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's ROCE % compare to VEEV and BTSG?
RaySearch Laboratories AB's ROCE % of 18.86% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.43. RaySearch Laboratories AB's value of 18.86% is 193.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.43, based on 645 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current ROCE % of 18.86% is 193.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current ROCE % is 18.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (STU:27R) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.14, compared to a current price of €19.38 — trading 13.1% above its estimated fair value. The current ROCE % is 18.86% and 193.3% above the Healthcare Providers & Services industry median of 6.43. RaySearch Laboratories AB's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For RaySearch Laboratories AB (STU:27R), the current ROCE % is 18.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaySearch Laboratories AB (STU:27R) Overvalued in 2026?

Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued. The current stock price of €19.38 is trading 13.1% above its estimated GF Value™ of €17.14. GuruFocus considers RaySearch Laboratories AB to be Modestly Overvalued.

Key valuation signals for STU:27R:

  • ROCE %: 18.86%
  • GF Value™: €17.14 vs. price of €19.38 (13.1% above fair value)
  • GF Score™: 83/100 with 2 warning signs
  • Industry Position: 193.3% above the Healthcare Providers & Services median

No single metric tells the full story. See the STU:27R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaySearch Laboratories AB Business Description

Address Eugeniavagen 18C, Stockholm, SWE, 113 68
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
83GF Score

Get the complete analysis for STU:27R

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.38
Price
€17.14
GF Value